Literature DB >> 12688330

Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1).

Alessandra Tucci1, Stefania Bonadonna, Chiara Cattaneo, Marco Ungari, Andrea Giustina, Rossi Guiseppe.   

Abstract

We present a female patient with monoclonal gammopathy of undetermined significance who has remained stable for five years but evolved to overt myeloma in strict temporal relationship with the diagnosis of GH-secreting pituitary macroadenoma. IGF-I serum levels correlated with serum and urine M component. Since the in vitro role of IGF-I on proliferation and survival of normal and neoplastic plasma cells has been recently emphasized, the pathogenetic link between acromegaly and transformation of gammopathy to overt myeloma in this case is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12688330     DOI: 10.1080/1042819021000037895

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

2.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

Review 3.  Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Authors:  Arun Balakumaran; Pamela Gehron Robey; Neal Fedarko; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

Review 4.  Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

Authors:  Gabriele Zoppoli; Federico Bianchi; Andrea Bruzzone; Alessandro Calvia; Caterina Oneto; Caterina Passalia; Enrico Balleari; Davide Bedognetti; Elena Ponomareva; Elena Nazzari; Lara Castelletti; Lucio Castellan; Francesco Minuto; Riccardo Ghio; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

5.  Hematologic neoplasias and acromegaly.

Authors:  Flavia Regina P Barbosa; Leonardo Vieira Neto; Giovanna Aparecida B Lima; Luiz Eduardo Wildemberg; Rodrigo Portugal; Monica R Gadelha
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

6.  Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Tara M Tancred; Andrew R Belch; Tony Reiman; Linda M Pilarski; Julia Kirshner
Journal:  J Histochem Cytochem       Date:  2008-11-11       Impact factor: 2.479

7.  The resistance mechanisms of proteasome inhibitor bortezomib.

Authors:  Shuqing Lü; Jianmin Wang
Journal:  Biomark Res       Date:  2013-03-01

8.  Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.

Authors:  Claudia Greco; Gaetano Vitelli; Giuseppe Vercillo; Rosa Vona; Diana Giannarelli; Isabella Sperduti; Francesco Pisani; Ettore Capoluongo; Maria Concetta Petti; Franco Ameglio
Journal:  J Exp Clin Cancer Res       Date:  2009-03-10

9.  Multiple myeloma in a patient with acromegaly.

Authors:  Yu Mi Kang; Jong Han Choi; Min Jung Lee; Ari Ahn; Chan Jeoung Park; Kiju Chang; Seyoung Seo; Sun In Hong; Min Seon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2014-08-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.